NeuroSense Therapeutics Ltd NRSN shares are soaring Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
PrimeC is designed to synergistically target several key mechanisms of amyotrophic lateral sclerosis (ALS). It's composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.
The pharmacokinetic study aims to evaluate the effects of food on the bioavailability of PrimeC.
NeuroSense already completed a Phase IIa clinical study of PrimeC which successfully met its safety and efficacy endpoints. The company plans to initiate a Phase IIb double-blind placebo-controlled multinational study in the second quarter.
See Also: Why Anaplan Shares Are Soaring Today
NRSN 52-Week Range: $1.30 - $4.69
NeuroSense shares were up 290.4% at $6.12 at time of publication.
Photo: jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
